Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 415 shares of the company’s stock after selling 53 shares during the quarter. TD Private Client Wealth LLC’s holdings in Medpace were worth $138,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Zeno Equity Partners LLP boosted its holdings in Medpace by 24.9% during the 4th quarter. Zeno Equity Partners LLP now owns 60,740 shares of the company’s stock valued at $20,180,000 after acquiring an additional 12,121 shares during the period. Enhancing Capital LLC acquired a new stake in shares of Medpace during the fourth quarter worth about $476,000. Xponance Inc. boosted its stake in shares of Medpace by 3.4% in the fourth quarter. Xponance Inc. now owns 5,177 shares of the company’s stock valued at $1,720,000 after purchasing an additional 171 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Medpace by 17.0% in the fourth quarter. Advisors Asset Management Inc. now owns 7,195 shares of the company’s stock valued at $2,390,000 after purchasing an additional 1,046 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in Medpace by 738.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 120,928 shares of the company’s stock worth $40,176,000 after buying an additional 106,498 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ:MEDP opened at $324.51 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The stock has a market cap of $9.89 billion, a P/E ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47. The stock has a 50-day simple moving average of $337.16 and a 200-day simple moving average of $339.57.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on MEDP shares. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Leerink Partners began coverage on Medpace in a research note on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.